2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2105

The Comparative Efficacy of Pneumocystis Pneumonia Prophylactic Regimens in Patients with Connective Tissue Diseases Receiving Prolonged High-dose Glucocorticoids
Abstract Number: 1333

The Comparative Risk of Osteoporotic Fractures Among Patients with Rheumatoid Arthritis Receiving TNF Inhibitors versus Other Biologics: A Nation-wide Cohort Study in Korea
Abstract Number: 1844

The Contribution of Disease Activity, Depression, and Anxiety to Health-Related and Non-Health-Related Quality of Life in US and Filipino Patients with SLE
Abstract Number: 2596

The Contribution of Left Heart Disease in Patients with Systemic Sclerosis-associated Pulmonary Hypertension Having Normal Pulmonary Artery Wedge Pressure
Abstract Number: 556

The Correlation of Bone Bridge and Low Bone Mineral Density Measured by Quantitative Computed Tomography in Patients with Ankylosing Spondylitis
Abstract Number: 2299

The Course of Disability in Early Rheumatoid Arthritis over 10 Years of Follow-up in Women and Men – Comparison with the General Population
Abstract Number: 449

The Course of Disability Related to Function of the Upper Extremities in Early Rheumatoid Arthritis over 10 Years of Follow-up
Abstract Number: 2638

The Cumulative Burden of Damage for Patients with Eosinophilic Granulomatosis with Polyangiitis
Abstract Number: 2060

The Current State of Big Data Use and Artificial Intelligence in RMDs: A Systematic Literature Review Informing EULAR Recommendations
Abstract Number: 2490

The Cutaneous Microbiome of Psoriatic Disease Is Influenced by Disease Susceptibility HLA Alleles but Not Clinical Phenotype
Abstract Number: 1777

The Deubiquitinase TRABID Is a Potential Therapeutic Target in Spondyloarthritis
Abstract Number: 1124

The Direct and Indirect Costs of Illness Associated with Systemic Lupus Erythematosus in the USA, UK, France, and Germany: A Structured Review
Abstract Number: 1060

The Diversity and Community Metrics of the Esophageal Microbiome of SSc Patients
Abstract Number: 105

The DLEU2/miR-15a/16-1 Cluster Inhibit Foxp3+ Treg Cells in Salivary Glands of pSS via Targeting Foxp3
Abstract Number: 2722

The down Syndrome Arthropathy Cohort in the New Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: Clinical Characteristics, Treatment and Outcomes

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].